Investment analysts at StockNews.com initiated coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR – Get Free Report) in a research note issued on Monday. The firm set a “sell” rating on the biotechnology company’s stock.
Eiger BioPharmaceuticals Stock Performance
Shares of EIGR stock opened at $2.30 on Monday. The stock has a fifty day moving average price of $5.49 and a 200 day moving average price of $7.40. The stock has a market cap of $3.40 million, a PE ratio of -0.04 and a beta of 1.83. Eiger BioPharmaceuticals has a 1 year low of $1.10 and a 1 year high of $43.35.
Hedge Funds Weigh In On Eiger BioPharmaceuticals
Several hedge funds and other institutional investors have recently bought and sold shares of EIGR. Legal & General Group Plc raised its holdings in Eiger BioPharmaceuticals by 62.0% during the second quarter. Legal & General Group Plc now owns 4,327 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 1,656 shares during the last quarter. Ergoteles LLC acquired a new position in Eiger BioPharmaceuticals during the second quarter worth $29,000. Marshall Wace LLP purchased a new position in Eiger BioPharmaceuticals during the fourth quarter worth $29,000. Annandale Capital LLC increased its position in Eiger BioPharmaceuticals by 22.3% during the fourth quarter. Annandale Capital LLC now owns 36,700 shares of the biotechnology company’s stock worth $43,000 after buying an additional 6,700 shares in the last quarter. Finally, Jane Street Group LLC increased its position in Eiger BioPharmaceuticals by 310.2% during the first quarter. Jane Street Group LLC now owns 56,661 shares of the biotechnology company’s stock worth $51,000 after buying an additional 42,848 shares in the last quarter. 62.46% of the stock is owned by institutional investors and hedge funds.
About Eiger BioPharmaceuticals
Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.
Featured Stories
- Five stocks we like better than Eiger BioPharmaceuticals
- Bank Stocks – Best Bank Stocks to Invest In
- MarketBeat Week in Review – 4/1 – 4/5
- Conference Calls and Individual Investors
- Beazer Homes USA is an Overlooked Opportunity in Housing
- 3 Ways To Invest In Coffee, Other Than Drinking It
- 5 Stocks in the Current Bull Market with Upside to Come
Receive News & Ratings for Eiger BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
